

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 April 2011 (28.04.2011)

(10) International Publication Number  
WO 2011/049833 A1

(51) International Patent Classification:

A61F 2/00 (2006.01)

(74) Agent: DETWEILER, Sean, D.; Morse, Barnes-brown & Pendleton, P.C., Reservoir Place, 1601 Trapelo Road, Suite 205, Waltham, MA 02451 (US).

(21) International Application Number:

PCT/US2010/052899

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:

15 October 2010 (15.10.2010)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12/581,582 19 October 2009 (19.10.2009) US

(71) Applicant (for all designated States except US): ATRIUM MEDICAL CORPORATION [US/US]; 5 Wentworth Drive, Hudson, NH 03051 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SWANICK, Thomas, M. [US/US]; 60 Sawmill Road, Hillsborough, NH 03244 (US). BIENKIEWICZ, Joe [US/US]; 3 Parker Circle, Westford, MA 01886 (US). FERRARO, Joseph [US/US]; 36 Sherwood Road, Londonderry, NH 03053 (US). MARTAKOS, Paul [US/US]; 1 Regis Drive, Pelham, NH 03076 (US). FAUCHER, Keith, M. [US/US]; 36 Alpine Street, Milford, NH 03055 (US). DALE, Alicia [US/US]; 5 Wentworth Drive, Hudson, NH 03051 (US).

Published:

— with international search report (Art. 21(3))

(54) Title: TISSUE-SEPARATING FATTY ACID ADHESION BARRIER




Figure 1

100

(57) Abstract: Exemplary embodiments of the present invention provide adhesion barriers having anti-adhesion and tissue fixating properties. The adhesion barriers are formed of fatty acid based films. The fatty acid-based films may be formed from fatty acid-derived biomaterials. The films may be coated with, or may include, tissue fixating materials to create the adhesion barrier. The adhesion barriers are well tolerated by the body, have anti-inflammation properties, fixate, well to tissue, and have a residence time sufficient to prevent post- surgical adhesions.

WO 2011/049833 A1

## TISSUE-SEPARATING FATTY ACID ADHESION BARRIER

### Related Applications

This application claims priority to, and the benefit of, U.S. Application No. 12/581,582, filed October 19, 2009, which is a continuation-in-part of the following: U.S. patent application Ser. No. 11/237,420 entitled "Barrier Layer," filed on Sep. 28, 2005; U.S. patent application Ser. No. 11/237,264 entitled "A Stand-Alone Film and Methods for Making the Same," filed on Sep. 28, 2005; U.S. patent application Ser. No. 11/978,840 entitled "Coated Surgical Mesh," filed on Oct. 30, 2007; and U.S. patent application Ser. No. 12/401,243 entitled "Fatty-Acid Based Particles," filed on Mar. 10, 2009. The contents of the aforementioned patent applications are incorporated herein by reference.

### Field of the Invention

The present invention generally relates to a tissue-separating adhesion barrier.

### Background

Medical films are often used in surgical settings as a physical barrier to separate certain organs from adjacent tissues and medical devices following surgical intervention or blunt dissection to help minimize adhesion formation post-surgery. For example, SEPRAFILM® (a film composed of chemically modified sugars), a product of Genzyme Corporation of Cambridge, MA, is used in abdominal or pelvic surgeries as an implantable treatment intended to reduce the incidence, extent, and severity of postoperative adhesion formation between different tissues and organs and implantable medical devices such as soft tissue support membranes and mesh, or combinations of non-absorbable materials and meshes.

One example of a medical film is described in U.S. Patent Application No. 5,017,229. The film of the '229 patent is formed from a water insoluble, gel that includes the reaction product of hyaluronic acid ("HA"), a polyanionic polysaccharide, and an activating agent. The gel described in the '229 patent can be provided in the form of an adhesion prevention composition, such as a membrane or composition suitable for

incorporation into a syringe. The gel is formed into a film by being cast into a sheet form, extruded, compressed, or allowed to dehydrate in a flat sheet. When modified with polysaccharide, the biodegradable film forms the above-described SEPRAFILM® adhesion-limiting or adhesion-barrier product made commercially available as a dehydrated bio-dissolvable single layer sheet.

Implantable medical films may be placed at a target site, for example, between two tissues, during surgery. In order to prevent or limit postoperative adhesion formation, the film should remain at the target site for a requisite period of time. For example, some sources have noted that barrier functionality is required between 3 days and 10 days post-surgery (see, Peritoneal Surgery by Gere, S. DiZerega, Alan H. DeCherney, Published by Springer, 2000, page 21). In order to achieve this barrier functionality, a biodegradable film should remain in place at the target site and it should be absorbed by the body for a sufficient period of time to provide barrier functionality post surgery when adhesions form.

However, conventional medical films are resorbed into the body too quickly to provide effective barrier functionality during the time in which postoperative adhesion formation typically occurs. For example, many cross-linked carboxymethylcellulose (“CMC”) based films may be absorbed in-vivo within 7 days.

### Summary

As described in more detail below, a fatty-acid based film, such as a film made of fish oil, constructed with fixating materials, such as carboxymethylcellulose (“CMC”) or Na-CMC, may be provided to fixate the film and prevent migration of the film. Despite inflammatory characteristics of CMC and the rapid resorption characteristics of CMC and Na-CMC, the adhesion barrier is well-tolerated by the body, is non-inflammatory, does not migrate from a target site, and does not require cross-linking of the CMC. The adhesion barrier of the present invention effectively delays resorption to an acceptable post implantation duration (e.g., greater than 7 days). The combination of a fatty-acid based film with a fixating material such as CMC or Na-CMC results in an unexpected synergistic effect. Specifically, non-cross-linked CMC in the presence of the fatty-acid based film does not absorb into the body as quickly as cross-linked CMC that is not in the

presence of a fatty acid. As a result, the fixating portion of the adhesion barrier is absorbed into the body at a much slower rate than other CMC-based films, so that barrier functionality is provided over the time period that adhesions are likely to form.

In some exemplary embodiments of the invention, the adhesion barrier is in the form of an emulsion. The emulsion may include fatty-acid based particles immersed in an emulsion base. The fatty-acid based particles may be formed by fragmenting a fatty-acid derived biomaterial associated with a cryogenic liquid. The emulsion base may include a mixture of a fixating material, such as CMC, with an aqueous-based solution, such as (but not limited to) water, saline, or Ringer's lactate solution.

Exemplary embodiments of the present invention provide adhesion barriers and methods for formulating the adhesion barriers. In accordance with one exemplary embodiment of the present invention, the adhesion barrier takes the form of a fatty acid based film composition. The adhesion barrier includes a fatty acid based film derived from a cross-linked fatty acid-derived biomaterial and a tissue fixating coating formed from a material surrounding the fatty acid based film. The tissue fixating coating may be applied by any means known in the art.

In accordance with aspects of the present invention, the fatty acid-derived biomaterial is an omega-3 fatty acid. The fatty acid-derived biomaterial may, or may not be, crosslinked. The fatty acid-derived biomaterial may contain at least one lipid or omega-3 fatty acid; for example, the fatty acid-derived biomaterial may be a fish oil. The fish oil may further comprise vitamin E.

In accordance with one exemplary embodiment, the coherent material may be a polyanionic polysaccharide, such as carboxymethylcellulose (CMC). In accordance with another exemplary embodiment, the coherent material comprises a salt of CMC, such as sodium carboxymethylcellulose (Na-CMC).

In accordance with further aspects of the present invention, the fatty acid-derived biomaterial may reduce inflammation associated with the fixating material. In some embodiments, the adhesion barrier does not migrate from a surgical site of placement, while in further embodiments, the adhesion barrier has a residence time that is sufficient to prevent post-surgical adhesions.

### **Brief Description of the Drawings**

The foregoing and other aspects, embodiments, objects, features and advantages of the invention can be more fully understood from the following description in conjunction with the accompanying drawings. In the drawings like reference characters generally refer to like features and structural elements throughout the various figures. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.

**Figure 1** depicts an adhesion barrier in accordance with one example embodiment of the present invention.

**Figure 2** is a flow chart depicting an exemplary method for fabricating an exemplary adhesion barrier in accordance with one example embodiment of the present invention.

**Figure 3** depicts an adhesion barrier in accordance with one example embodiment of the present invention.

**Figure 4** depicts an adhesion barrier in accordance with one example embodiment of the present invention.

**Figure 5** depicts an adhesion barrier created as an emulsion in accordance with one example embodiment of the present invention.

**Figure 6** is a flow chart depicting an exemplary method for fabricating an exemplary adhesion barrier as depicted in **Figure 5**.

### **Detailed Description**

Exemplary aspects and embodiments of the present invention provide adhesion barriers formed from fatty acid-based films or fatty acid-based particles. The adhesion barriers have the fixating properties of materials, such as CMC-based films, with an additional unexpected synergistic effect, which substantially slows the rate at which the

tissue fixating portion of the adhesion barrier is absorbed without requiring crosslinking of the CMC component.

#### *Conventional Films*

In some conventional products, hydrophilic tissue fixating components such as poly(ethylene glycol), poly(ethylene oxide), poly(HEMA), poly(N-vinyl pyrrolidone), poly(acrylic acid), carboxymethyl cellulose (CMC), chitosan, etc. are used to provide fixation of the film. This fixation can address the problem of film mobility or migration. However, these hydrophilic materials may exhibit appreciable foreign body reaction and inflammation, which are undesirable characteristics (see, e.g. European Patent Application EP20020080404).

Further, manufacturing these conventional tissue fixating components poses additional challenges. Specifically, the above tissue fixating components must be chemically crosslinked via functional end group modification, or by the use of chemical crosslinking agents, to provide suitable mechanical integrity for handling and insolubility in a wet environment. The use of chemical crosslinkers such as gluteraldehyde or aziridines requires the additional step of removing the excess crosslinking agents by washing or soaking, as these compounds are often less biocompatible than the desired hydrogel materials. These additional steps add to the expense and difficulty of the manufacturing process.

As noted above, films may be made of a polyanionic polysaccharide and hyaluronic acid. One preferred polyanionic polysaccharide used to make a film described in the '229 patent is CMC. The film in the '229 patent is formed with HA and CMC (“HA/CMC”). However, it has been noted that the method for preparing this type of film can be problematic because of the procedure for removing biologically toxic materials generated in the preparation (see, e.g., U.S. Patent Application Publication No. 2003/0124087). The '087 application notes that the hydration process in an HA/CMC preparation may cause difficulties in treatment and operation.

One alternative to HA/CMC is sodium carboxymethylcellulose (“Na-CMC”). While Na-CMC is effective as an anti-adhesion agent, it is difficult to apply Na-CMC as an anti-adhesion barrier because it is absorbed in the body too fast to be effective as an

adhesion barrier. Fast absorption of a CMC-based film into the body is problematic, because the film is resorbed before it can act as an effective adhesion barrier. For example, HA/CMC films can be absorbed in 7 days, while, as noted above, barrier functionality may be required between 3 days and 10 days post-surgery, and in some instances up to 8 weeks of barrier functionality is necessary.

Further, films made from salts of CMC, such as Na-CMC, can be difficult or problematic to produce. Producing these films may require immobilization of the CMC or stabilization by cross-linking, because the Na and CMC readily dissociate in aqueous media, allowing the CMC to dissolve. Cross-linking is the process of chemically joining two or more molecules with a chemical bond. Cross-linking of CMC can be accomplished, for example, by irradiating the CMC (see, e.g., Fei et al., Hydragel of Biodegradable Cellulose Derivative. I. Radiation-Induced Crosslinking of CMC, *Journal of Applied Polymer Science*, vol. 78, pp. 278-283 (2000)).

Without immobilization or stabilization of the CMC by cross-linking, the transition from solid to liquid significantly reduces the ability of Na-CMC films to provide effective barrier protection. Cross-linking CMC results in additional problems. Radiation-induced cross-linking of unmodified CMC requires the presence of a medium such as water to mobilize the macromolecules and allow for assembly. Solid phase irradiation of CMC results in degradation of the material by scission of the glycosidic bond.

Cross-linked CMC films also have the limit of being quickly resorbed in-vivo, i.e. within 7 days. In addition, CMC films are known to cause inflammation, and may lack adhesiveness and affinity (see, e.g., '087 application at paragraphs [0009] - [0013]).

#### *Exemplary Embodiments*

In contrast to conventional adhesion barriers, embodiments of the present invention provide an adhesion barrier that resides at a target site for a sufficient time to provide barrier functionality, does not require that the CMC component be cross-linked, and does not provoke a significant inflammatory response. In accordance with exemplary embodiments of the present invention, fatty acid-based films or fatty acid-based particles composed of fatty acid-derived biomaterials are used as a resorbable

tissue-separating adhesion barrier material. Omega-3 and omega-6 fatty acids are examples of fatty acids that may be obtained from, for example, fish oil. Omega-3 fatty acids include eicosapentaenoic acid (EPA), docosahexanoic acid (DHA), and alpha-linolenic acid (ALA).

Fatty acid-based barriers composed of fatty acid-derived biomaterials effectively separate adjacent tissue surfaces, are well tolerated by the body, and do not exhibit the inflammatory response typical of other resorbable and permanent implant materials. While CMC-based films adhere well to tissue, CMC-based films readily dissolve in aqueous media in about 7 days.

Combining fatty acid-based films or particles with fixating materials as described herein results in an effective anti-adhesion barrier with fixating and anti-inflammation properties. Additionally, combining these two types of materials also yields an unexpected synergistic result – specifically, an adhesion barrier formed from a combination of CMC and a fatty acid-based film or fatty acid-based particles remains at the treatment site providing barrier functionality beyond 7 days and for up to 28 days or longer, without crosslinking the CMC. This provides sufficient residence time to effectively provide post-surgery barrier functionality.

Prior to describing the aspects of the present invention, it should be noted that, as used herein, the term “biocompatible,” means compatible with living tissue (e.g., not toxic or injurious). Biocompatible compounds may hydrolyze into non-inflammatory components that are subsequently bio-absorbed by surrounding tissue. Biocompatible compounds are also referred to herein as “biomaterials.”

Films include substances formed by compressing a gel, or by allowing or causing a gel to dehydrate, or by curing the gel using heat and/or light in various ways. In addition, films can be chemically formed in accordance with processes known by those of ordinary skill in the art.

In addition to films, exemplary embodiments of the present invention include emulsions. An emulsion is a solution of two or more immiscible liquids. In one exemplary embodiment, the emulsion is formed from an emulsion base mixed with fatty-

acid based particles. The fatty-acid based particles may be derived from a fatty-acid based film.

As used herein, a fatty-acid based material is meant to encompass any form of material that the fatty acid may take, including films and particles.

#### *Exemplary Film Embodiments*

FIG. 1 depicts an adhesion barrier 100 according to one embodiment of the present invention. The adhesion barrier 100 includes a fatty acid-based film 110. The fatty acid-based film 110 may be formed by any of the methods known in the art. In one embodiment, a crosslinked, fatty acid-derived biomaterial comprises an oil that may be natural or derived from synthetic sources and is used to form the fatty acid-based film 110. The crosslinked, fatty acid-derived biomaterial can comprise a biological oil, such as an oil containing at least one lipid or omega-3 fatty acid, including a fish oil. The biomaterial further can include vitamin E.

The adhesion barrier 100 also includes a tissue fixating coating 120 formed from an fixating material. In one embodiment, the fixating material is a polyanionic polysaccharide. In another embodiment, the fixating material comprises carboxymethylcellulose (CMC). In yet another embodiment, the fixating material comprises sodium carboxymethylcellulose (Na-CMC).

FIG. 2 is a flow chart depicting an exemplary method for fabricating the adhesion barrier 100. At step 210, a fatty acid-based film 110 is prepared by one of the methods known in the art. For example, as described in U.S. Patent Application No. 11/237,420, fish oil may be exposed to heating and/or UV irradiation to form a cross-linked, fatty acid-derived biomaterial such as a gel. The gel may further be compressed or dehydrated to form a film. One of ordinary skill in the art will appreciate that other methodologies may be utilized to form the fatty acid-based film 110, and the present invention is by no means limited to the particular methods described in the above-referenced application or patent.

The oil component may also be hardened, as described in the '420 application, in addition to other known methodologies. The step of hardening can include hardening, or

curing, such as by introduction of UV light, heat, or oxygen, chemical curing, or other curing or hardening method. The purpose of the hardening or curing is to transform the more liquid consistency of the oil component or oil composition into a more solid film, while still maintaining sufficient flexibility to allow bending and wrapping of the film as desired.

In some embodiments, the oil component is subjected to a surface treatment prior to coating, such as a plasma treatment.

At step 220, the fatty acid-based film 110 is optionally cut to an appropriate size. The final dimensions of the cut fatty acid-based film 110 will be dependent on the specific application.

At step 230, a coating solution of tissue fixating material is prepared. In accordance with one exemplary embodiment of the present invention, the coating solution is composed of 0.1%-5% (weight/volume) non-crosslinked high molecular weight Na-CMC with a degree of substitution of 0.65-0.85 (although degrees of substitution below 0.65 and up to a theoretical limit of 3 are also acceptable) in a water solution, such as deionized water or Sterile Water for Injection (SWFI). Optionally, the coating solution may include a plasticizing agent such as glycerin, propylene glycol, poly ethylene glycol, triacetin citrate or triacetin.

At weight/volume concentrations higher than about 5%, the solution becomes a solid-like gel, which may be difficult to work with. Generally, most solutions with a concentration of less than 5% are physically workable, but care should be taken with the mass loading of, for example, Na-CMC on the surface of the film. If there is too little Na-CMC it will result in an adhesion barrier with insufficient tissue fixation. Low Na-CMC concentration may require many coating applications to achieve to the desired loading. In one embodiment, a weight/volume concentration of 2% is used. We have found that a minimum dry loading of 1.0mg/cm<sup>2</sup> may be used to achieve adequate tissue fixation in-vivo.

A high molecular weight of, for example, 700,000 for Na-CMC may be used for the tissue fixating material. In separate evaluations of chitosan, the inventors have found that tissue fixation appears to increase with molecular weight.

Based on experimental observations, and not being bound by theory, the tissue fixation is due to the hydroscopicity of the coating. Because the hydroscopicity increases with increasing degrees of substitution, all practical ranges of degrees of substitution are acceptable in the present invention. A degree of substitution of between 0.65 – 1.2 is a range that is practical and readily available.

At step 240, the coating solution is applied to the fatty acid-based film 110 using any standard coating method, such as dip coating, spray coating, brushing, casting, or spin coating. At step 250, the coating is allowed to dry for a suitable amount of time, for example 2-24 hours. Alternatively, an apparatus may be used to accelerate drying through various known methods, so long as the temperature of the coating solution is not raised too high (resulting in an aqueous or gelatinous coating). For example, the film may be vacuum dried.

As an alternative to coating the fatty acid-based film with a fixating material, the fixating material may be introduced into the original oil or gel before it is formed into a film. An example of an adhesion barrier in accordance with such an embodiment is shown in FIG. 3. As shown, the adhesion barrier 300 is formed of a fatty acid-based film 310. The adhesion barrier 300 further includes fixating particles 320 formed from a fixating material, such as Na-CMC. Such an embodiment may be formed, for example, by a pressed particle method in which particles of a fatty acid, such as O3FA, are formed and particles of a fixating material are formed. The two types of particles are then mixed together and pressed to form an adhesion barrier. One of ordinary skill in the art will appreciate other methods for combining two materials together to form an intermixed, composite, type of material. All such methods, to the extent compatible with the materials discussed herein, are contemplated in the present invention.

FIG. 4 depicts another alternative embodiment of the present invention. In the adhesion barrier depicted in FIG. 4, the adhesion barrier 400 is formed of a fatty acid-based film 410. The fatty acid-based film 410 is coated with a fixating coating 420 on only one side. Such an adhesion barrier may be formed, for example, by brushing or spraying the fixating coating 420 on only a single side of the fatty-acid based film 410. Other means of coating fatty-acid based film 410 on a single side will be apparent to one

having ordinary skill in the art in light of the present disclosure. Alternatively, the fatty acid-based film 410 may be coated on two or more surfaces without entirely surrounding the fatty acid-based film. Accordingly, tissue fixation can be achieved on one or both sides of the fatty acid-based film.

#### *Exemplary Emulsion Embodiments*

FIG. 5 depicts another alternative embodiment of the present invention. The adhesion barrier 500 depicted in FIG. 5 is an emulsion of fatty-acid based particles 510 mixed with an emulsion base 520, such as a CMC and water mixture.

The fatty-acid based particles 510 may be formed by associating a cross-linked fatty acid-derived biomaterial with a cryogenic liquid and fragmenting the biomaterial/cryogenic liquid composition, such that fatty acid particles are formed. In one embodiment, the source of the cross-linked fatty acid-derived biomaterial is a fish oil, *e.g.*, a fish oil that has been heated or exposed to UV-radiation in order to cross link some or all of the fatty acids of the fish oil.

In one embodiment, associating the cross-linked fatty acid-derived biomaterial with a cryogenic liquid includes suspending, submerging, and surrounding the cross-linked fatty acid-derived biomaterial. In another embodiment, the cryogenic liquid comprises liquid nitrogen. The cross-linked fatty acid-derived biomaterial/cryogenic liquid composition can be fragmented using one or more of grinding, shearing, shocking, shattering, granulating, pulverizing, shredding, crushing, homogenizing, sonicating, vibrating, and/or milling. The cryogenic liquid can be substantially removed by evaporation, either before fragmentation or after the particles are formed.

The cross-linked, fatty acid-derived biomaterial can comprise an oil that may be natural or derived from synthetic sources. The cross-linked, fatty acid-derived biomaterial can comprise a biological oil, such as an oil containing at least one lipid or omega-3 fatty acid, such as a fish oil. The fish oil further can include vitamin E. As described herein, the fish oil is exposed to heating and/or UV irradiation to form a cross-linked, fatty acid-derived biomaterial (*e.g.*, gel). In one embodiment, before being associated with a cryogenic liquid, the cross-linked material is in the form of a film. In

another embodiment, the film is coarsely ground prior to association with the cryogenic liquid.

When the cross-linked, fatty acid-derived biomaterial is in the form of a film, a therapeutic agent can be loaded into the film before particle formation, during particle formation, or after particle formation. In still another embodiment, the film is coated with a therapeutic agent/solvent mixture. The therapeutic agent can be dissolved in a solvent, such as methanol or ethanol, and the therapeutic agent/solvent mixture can be applied to the film, *e.g.*, by dipping or spraying.

Once prepared, the fatty-acid based particles 510 can be soaked in a therapeutic agent dissolved in solvent, such as hexane, isopar, water, ethanol, methanol, proglyme, methylene chloride, acetonitrile, acetone, or MEK, and the solvent can be substantially removed, resulting in fatty acid particles associated with a therapeutic agent.

The therapeutic agent can be one or more of an antioxidant, anti-inflammatory agent, anti-coagulant agent, drug to alter lipid metabolism, anti-proliferative, anti-neoplastic, tissue growth stimulant, functional protein/factor delivery agent, anti-infective agent, imaging agent, anesthetic agent, chemotherapeutic agent, tissue absorption enhancer, anti-adhesion agent, germicide, analgesic, antiseptic, or pharmaceutically acceptable salts, esters, or prodrugs thereof. In particular embodiments, the therapeutic agent is selected from the group consisting of rapamycin, marcaine, Cyclosporine A (referred to herein as “CSA”), ISA 247 (referred to herein as “ISA”) and rifampicin.

In one embodiment, the mean particle size of the fatty-acid based particles 510 is in the range of about 1 micron to about 50 microns, *e.g.*, 1 micron to about 10 microns. In another embodiment, the particles have a distribution of size of about 1-20  $\mu\text{m}$  (v,0.1), 21-40  $\mu\text{m}$  (v,0.5), and 41-150  $\mu\text{m}$  (v,0.9).

The emulsion base 520 is a liquid or aqueous-based solution which does not combine with the fatty-acid based particles 510 when mixed. In one example, the emulsion base is a CMC and water mixture. Other suitable emulsion bases include, but

are not limited to, saline solutions and Ringer's lactate solution. The emulsion base may include a tissue coherent material.

FIG. 6 is a flowchart depicting an exemplary method for creating the adhesion barrier of FIG. 5. At step 610, an emulsion base solution is prepared. In one example, an emulsion base solution comprising a CMC and water mixture (4.2 % w/w) was prepared using a Silverson Homogenizer (8kRPM) and was allowed to swell at room temperature overnight.

At step 620, fatty-acid based film particles are prepared, as described above. Specifically, the fatty-acid based particles may be formed by: (a) combining a cross-linked, fatty acid-derived biomaterial (e.g., a cross-linked fish oil) and a therapeutic agent to form a first composition; (b) submerging, surrounding, or suspending the composition in a cryogenic liquid (c) fragmenting the composition; and (d) optionally removing the dispersing media.

The dispersing media may comprise a solvent that will not dissolve the therapeutic agent or the cross-linked, fatty acid-derived biomaterial. In still another embodiment, the solvent is hexane, Isopar, water, ethanol, methanol, Proglyme, methylene chloride, acetonitrile, acetone, MEK, liquid nitrogen, and other solvents that do not fully dissolve the therapeutic agent. In another embodiment, the cross-linked, fatty acid-derived biomaterial is in the form of a film. In another embodiment, the film is coarsely ground prior to association with the therapeutic agent.

The starting materials may be fragmented into solid particles by impacting the starting materials with a rod that is magnetically actuated. For example, a Spex Certiprep Cryomill (model 6750) can be used to fragment solid materials into particles. The composition can be placed in an enclosed vial, and a rod like impactor is enclosed in the vial. The vial is maintained at cryogenic temperatures, and the rod is rapidly oscillated in the vial by means of magnets.

In one example, fish oil was partially cured then cast into a thin film 6 mil (0.006") in thickness. The thin film was UV cured for 15 minutes, heat cured in an oven at 93°C for 24 hours, and then cooled for 24 hours. The cured fish oil films were ground

with a mortar and pestle in the presence of liquid nitrogen. The thin film particles were further ground using a cryogrinder for 8 cycles. In each of the 8 cycles, the cryogrinder was on for 2 minutes at speed 15 and off for 2 minutes. The particles were stored at – 20°C.

At step 630, the particles are homogenized with a fatty acid in order to form a fatty acid-based solution. In one exemplary embodiment, 1 gram of the particles was homogenized with 8 grams of fish oil using the Silverson Homogenizer (8kRPM) until all the particles were evenly dispersed.

At step 640, the emulsion base is mixed with the fatty acid-based solution to form an emulsion. In one example, the fatty acid-based solution was mixed with 31 grams of 4.2 % CMC gel (after swelling) using the Silverson Homogenizer (8kRPM).

At step 650, the emulsion is sterilized. For example, the emulsion may be e-beam sterilized at a dose of 23 kGy.

An exemplary emulsion was prepared following steps 610-650. The resulting emulsion had a viscosity in the range of 50,000 – 75,000 cP.

In use, the adhesion barrier of the present invention is applied at a target site, for example a surgical site. The adhesion barrier may be applied between two areas of interest – for example, between tissues, organs, meshes, or other non-absorbable materials. The fixating properties of the adhesion barrier cause the adhesion barrier to fixate to the areas of interest so that the barrier does not migrate from the target site.

Post surgery, the surgical incision is closed and the target site is allowed to heal. Under normal conditions without use of an adhesion barrier, adhesions would begin to form between the areas of interest. For example, fibrous bands may form between tissues and organs 3 to 10 days post surgery. When the adhesion barrier is present at the target site, the adhesion barrier prevents adhesions from forming. Because the adhesion barrier fixates sufficiently to the areas of interest, and because the adhesion barrier is absorbed into the body relatively slowly, the adhesion barrier is in place at the target site at the time adhesions would otherwise form.

After barrier functionality is no longer needed, the adhesion barrier is absorbed into the body.

Exemplary illustrative embodiments are described below.

*Example 1: Bench Top Force of Detachment – non Sterile Samples*

A coating solution composed of 2% (w/v) non-crosslinked high molecular weight Na-CMC with a degree of substitution of 0.65 (Sigma) in deionized water was applied to 15 one inch square fatty acid-based films and allowed to dry to form adhesion barriers in accordance with embodiments of the present invention. The adhesion barriers were placed on freshly slaughtered bovine intestine that was rinsed in tap water prior to testing. The adhesion barriers were allowed to remain on the tissue for 3 minutes before testing. A Chatillon gauge was used to measure the force of detachment in the direction parallel to the plane of adhesion between the adhesion barriers and the tissue. The maximum force measured on the Chatillon gauge for each sample was collected. 15 uncoated fatty acid-based films were measured for reference. The uncoated films had a mean force of detachment of 0.08 lbf. In contrast, the coated films forming adhesion barriers in accordance with embodiments of the present invention had a mean force detachment of 0.54 lbf.

*Example 2: In-vivo Results of a Fatty Acid-CMC Film in Minimizing Tissue to Tissue Adhesions*

Test samples of an adhesion barrier in accordance with exemplary embodiments of the present invention were produced using the methods described above in Example 1. The CMC was not modified to enhance crosslinking and no crosslinking facilitators were employed. The test samples were implanted in a rabbit sidewall model of adhesion prevention. Samples were sterilized using an electron beam at a dose of 22.5kGy. The cecum was fully abraded to produce punctate bleeding and a 3x5 cm section of the peritoneum was excised. This model yields dense adhesions in untreated animals. A 4x6 cm O3FA film coated with CMC was placed on the peritoneal defect with the coated side in direct contact with the sidewall. At 28 days post implant, the rabbits were sacrificed and the area of adhesions was graded.

Four rabbits were maintained as a control group with no treatment. Five rabbits were treated with the adhesion barriers. In the four control subjects, the mean area of adhesion was 100%. In the experimental subjects having the adhesion barriers, the mean area of adhesion was 8%.

As noted, no crosslinking facilitators were employed in this example. Electron beams are known to degrade previous solid CMC films which will result in faster absorption in-vivo. However, despite the use of e-beam sterilization, the results from Example 2 show that the adhesion barriers remained tissue coherent for at least 28 days.

*Example 3*

Crosslinking via radiation exposure is a method that can be used to increase the in-vivo residence time of aqueous CMC compositions. To evaluate the effect of radiation exposure on dry CMC films, a solution composed of 2% (w/v) Na-CMC with a degree of substitution of 0.7 (Hercules) in SWFI was diluted with SWFI in a solution:SWFI ratio of 5:2. The dilute solution was poured into a Teflon coated well plate and allowed to dry at room temperature for 24 hours, resulting in a thin solid film of CMC. The film was cut into several square pieces that were packaged separately. Several pieces were irradiated using a 10MeV electron beam source at a dose of 22.5kGy. Irradiated and non-irradiated samples were submerged in separate aluminum pans of deionized water and evaluated for solubility and maintenance/loss of structure. If the CMC films were crosslinked by the exposure to radiation, hydration of the films should result in some swelling with maintenance of the original square geometry. In contrast, both irradiated and non-irradiated films swelled and lost structure within about 10 minutes and were no longer detectable as solids or gels by 30 minutes, indicating that the CMC was fully mobile (not crosslinked or otherwise immobilized via chemical bonding) in both samples. The CMC solutions in the pans were allowed to evaporate over 48 hours at ambient room temperature, yielding uniformly thin solid films of CMC that conformed to the circular pan geometry at the bottom of the pan. Full and equal solubility of exposed and non-exposed CMC films is evidence that the electron beam exposure did not constructively limit the mobility of (i.e. crosslink) the CMC material.

To further evaluate the effect of radiation crosslinking on CMC in the presence of O3FA, two test samples of an adhesion barrier in accordance with exemplary embodiments of the present invention were produced using the methods described above in Example 1. Adhesion Barrier 1 was exposed to a 10MeV electron beam source with a dose of 22.5kGy. Adhesion Barrier 2 was not exposed to electron beam radiation. The adhesion barriers were weighed and exposed to 200mL of deionized water, with visual evaluation at 2, 5, and 69 hours. The adhesion barriers were then vacuum dried for 2 hours at 25mTorr. Measurements and observations are provided below in Table 1.

Table 1

Sample	E-beam Exposure	Film Area [cm <sup>2</sup> ]	Initial Mass [mg]	Observation after 2h in DI water	Observation after 5h in DI water	Observation after 69h in DI water	Final Mass [mg]	Mass/Area Lost [mg/cm <sup>2</sup> ]
1	Yes	27.72	499.1	Gel layer thickness of 3mm	Gel layer thickness of 1mm	No gel layer	438.9	2.17
2	No	23.18	367.3	Gel layer thickness of 3mm	Gel layer thickness of 1mm	No gel layer	317.6	2.14

The authors had previously determined that the coating method employed yields a coating mass density of 2.28 +/- 0.11 mg/cm<sup>2</sup> (mean +/- 1 $\sigma$ , n=12). Both adhesion barriers have mass losses (2.17 and 2.14 mg/cm<sup>2</sup>, respectively) that support the conclusion that the coating is fully soluble in DI water, and therefore not crosslinked or otherwise immobilized. Visual observations support this conclusion.

CMC in the presence of O3FA took between 5 and 69 hours to fully dissolve in DI water, whereas CMC only films were fully dissolved in 30 minutes. The presence of O3FA appears to slow the dissolution of CMC in DI water. This is independent of irradiation with electron beam.

*Example 4*

A coating solution composed of 2% (w/v) Na-CMC with a degree of substitution of 0.7 (Hercules) and 1% glycerin in SWFI was prepared. The coating solution was

applied to several fatty acid-based films and was allowed to dry to form adhesion barriers. The adhesion barriers exhibited excellent handling, as the coating was well plasticized. The adhesion barriers were sterilized using an electron beam at a dose of 22.5kGy and implanted in a rabbit sidewall model of adhesions. The cecum was fully abraded to produce punctate bleeding and a 3x5 cm section of the peritoneum as excised. A 4x6 cm film coated with CMC was placed on the peritoneal defect with the coated side in direct contact with the sidewall. At 28 days post implant, the rabbits were sacrificed and the area of adhesions was graded.

Four rabbits were maintained as a control group with no treatment. Five rabbits were treated with the adhesion barriers. In the four control subjects, the mean area of adhesion was 100%. In the experimental subjects having the adhesion barriers, the mean area of adhesion was 8%.

The results show that, in this study, the addition of a plasticizing agent had no effect on the efficacy of the adhesion barriers comprising an O3FA-CMC film, as the adhesion barrier did not migrate from the site of treatment. The results of this study show that the plasticized adhesion barrier was tissue fixating for at least 28 days.

*Example 5: O3FA film with tissue fixating chitosan coating.*

A coating solution composed of 4% (w/v) ChitoPharm S (MW = 50,000-1,000,000, Cognis) in a 1% acetic acid solution was dialyzed using a Fisherbrand regenerated cellulose dialysis tubing membrane with a molecular weight cut off of 3,500. The final coating solution pH was 6.27. The coating was applied to several 4x6 cm O3FA films and evaluated in a rabbit sidewall model of adhesion prevention. Samples were sterilized using E-beam at a dose of 22.5kGy. The cecum was fully abraded to produce punctate bleeding and a 3x5 cm section of the peritoneum was excised. This model yields dense adhesions in untreated animals. The 4x6 cm films coated with chitosan were placed on the peritoneal defect with the coated side in direct contact with the sidewall. At 28 days post implant, the rabbits were sacrificed and the area of adhesions was graded. Results are shown in the table below.

Group	Description	n	Mean Area of Adhesions (%)
1	control, no treatment	4	100
2	Chitosan Coating	5	34

*Example 6: Emulsion*

An adhesion barrier in the form of an emulsion, as depicted in Figure 5, was prepared according to the procedure described in Figure 6. Samples of the emulsion were stored at 4°C until being tested.

Test samples of the emulsion were examined in a rabbit sidewall model to assess adhesion prevention. The cecum was fully abraded to produce punctate bleeding and a 3x5 cm section of the peritoneum was excised. This model yields dense adhesions in untreated animals. 10 mL of the emulsion was applied to the peritoneal and sidewall injuries. At 28 days post implant, the rabbits were sacrificed and the area of adhesions was graded.

Results showed that three of the six animals tested had no adhesion formation (area = 0 %). The remaining three that did form adhesions had a tenacity of only 1, indicating that the adhesions were mild and easily dissectible. The average area of adhesion coverage was 28.3 % and the average tenacity score was 0.5. These results contrasted that of the control, untreated animal, as detailed in the table below.

Group	Description	n	Mean Area of Adhesions (%)	Tenacity
1	Control, no treatment	4	100	2.75
2	Emulsion	6	28.3	0.5

*Biocompatibility and in-vivo performance*

The process of making the fatty acid-based biomaterials as described in accordance with the present invention led to some unexpected chemical processes and characteristics in view of traditional scientific reports in the literature about the oxidation

of oils (J. Dubois et al. *JAOCs*. **1996**, Vol. 73, No. 6., pgs 787-794. H. Ohkawa et al., *Analytical Biochemistry*, **1979**, Vol. 95, pgs 351-358.; H.H. Draper, **2000**, Vol. 29, No. 11, pgs 1071-1077). Oil oxidation has traditionally been of concern for oil curing procedures due to the formation of reactive byproducts such as hydroperoxides and alpha-beta unsaturated aldehydes that are not considered to be biocompatible (H.C. Yeo et al. *Methods in Enzymology*. **1999**, Vol. 300, pgs 70-78.; S-S. Kim et al. *Lipids*. **1999**, Vol. 34, No. 5, pgs 489-496.). However, the oxidation of fatty acids from oils and fats are normal and important in the control of biochemical processes *in-vivo*. For example, the regulation of certain biochemical pathways, such as to promote or reduce inflammation, is controlled by different lipid oxidation products (V.N. Bochkov and N. Leitinger. *J. Mol. Med.* **2003**; Vol. 81, pgs 613-626). Additionally, omega-3 fatty acids are known to be important for human health and specifically EPA and DHA have anti-inflammatory properties *in-vivo*. However, EPA and DHA are not anti-inflammatory themselves, but it is the oxidative byproducts they are biochemically converted into that produce anti-inflammatory effects *in-vivo* (V.N. Bochkov and N. Leitinger, **2003**; L.J. Roberts II et al. *The Journal of Biological Chemistry*. **1998**; Vol. 273, No. 22, pgs 13605-13612.). Thus, although there are certain oil oxidation products that are not biocompatible, there are also several others that have positive biochemical properties *in-vivo* (V.N. Bochkov and N. Leitinger, **2003**; F.M. Sacks and H. Campos. *J Clin Endocrinol Metab*. **2006**; Vol. 91, No. 2, pgs 398-400; A. Mishra et al. *Arterioscler Thromb Vasc Biol*. **2004**; pgs 1621-1627.). Thus, by selecting the appropriate process conditions, an oil-derived cross-linked hydrophobic biomaterial can be created and controlled using oil oxidation chemistry with a final chemical profile that will have a favorable biological performance *in-vivo*.

The process of making an oil-derived hydrophobic non-polymeric biomaterial in accordance with the present invention leads to a final chemical profile that is biocompatible, minimizes adhesion formation, acts as a tissue separating barrier, and is non-inflammatory with respect to the material chemistry and the products produced upon hydrolysis and absorption by the body *in-vivo*. These properties are due to several unique characteristics of the fatty acid-derived biomaterials in embodiments of the present invention.

One aspect of the present invention is that no toxic, short-chained cross-linking agents (such as glutaraldehyde) are used to form the oil-derived biomaterials and thus the adhesion barrier of the invention. It has been previously demonstrated in the literature that short chain cross-linking agents can elute during hydrolysis of biodegradable polymers and cause local tissue inflammation. The process of creating oil-derived biomaterials does not involve cross-linking agents because the oil is cured into a coating using oil autoxidation or photo-oxidation chemistry. The oxidation process results in the formation of carboxyl and hydroxyl functional groups that allow for the oil-derived biomaterial to become hydrated very rapidly and become slippery, which allows for frictional injury during and after implantation to be significantly reduced and/or eliminated. The methods of making the oil-derived biomaterials described in embodiments of the present invention allow the alkyl chains of the fatty acid, glyceride and other lipid byproducts present in the coating to be disordered, which creates a coating that is flexible and aids in handling of the material while being implanted.

There are several individual chemical components of the present inventive materials that aid in biocompatibility and the low to non-inflammatory response observed *in-vivo*. One aspect of exemplary embodiments of the present invention is that the process of creating an oil-derived biomaterial used to form the adhesion barrier as described herein results in low to non-detectable amounts of oxidized lipid byproducts of biocompatibility concern, such as aldehydes. These products are either almost completely reacted or volatilized during the curing process as described in exemplary embodiments of the present invention. The process of creating an oil-derived biomaterial largely preserves the esters of the native oil triglycerides and forms ester and/or lactone cross-links, which are biocompatible (K. Park et al., 1993; J.M. Andersen, 1995).

In addition to general chemical properties of an oil-derived biomaterial that assists in its biocompatibility, there are also specific chemical components that have positive biological properties. Another aspect is that the fatty acid chemistry produced upon creation of an oil-derived biomaterial is similar to the fatty acid chemistry of tissue. Thus, as fatty acids are eluting from the adhesion barrier they are not viewed as being “foreign” by the body and do not cause an inflammatory response. In fact, C14 (myristic) and C16 (palmitic) fatty acids present in the adhesion barrier have been shown

in the literature to reduce production of  $\alpha$ -TNF, an inflammatory cytokine. The expression of  $\alpha$ -TNF has been identified as one of the key cytokines responsible for “turning on” inflammation in the peritoneal cavity after hernia repair, which can then lead to abnormal healing and adhesion formation (Y.C. Cheong et. al., 2001).  $\alpha$ -TNF is also an important cytokine in vascular injury and inflammation (D.E. Drachman and D.I. Simon, 2005; S.E. Goldblum, 1989), such as vascular injury caused during a stent deployment. In addition to the fatty acids just specified, there have also been additional oxidized fatty acids identified that have anti-inflammatory properties. Another component identified from the fatty acid-derived biomaterials as described herein are delta-lactones (*i.e.*, 6-membered ring cyclic esters). Delta-lactones have been identified as having anti-tumor properties (H. Tanaka et. al. *Life Sciences* 2007; Vol. 80, pgs 1851-1855).

The components identified herein are not meant to be limiting in scope to the present invention, as changes in starting oil composition and/or process conditions can invariably alter the fatty acid and/or oxidative byproduct profiles and can be tailored as needed depending on the intended purpose and site of application of the fatty acid-derived biomaterial.

In summary, the biocompatibility and observed *in-vivo* performance of fatty acid-derived biomaterials that form the adhesion barrier described herein are due to the elution of fatty acids during hydrolysis of the material during implantation and healing and are not only beneficial as to prevent a foreign body response *in-vivo* due to the similarity of the fatty acid composition of the material to native tissue (*i.e.*, a biological “stealth” coating), but the specific fatty acids and/or other lipid oxidation components eluting from the coating aid in preventing foreign body reactions and reducing or eliminating inflammation, which leads to improved patient outcomes. Additionally, the fatty acid and glyceride components eluted from the fatty acid-derived biomaterial forming the fatty acid-based film of the adhesion barrier are able to be absorbed by local tissue and metabolized by cells, in, for example, the Citric Acid Cycle (M. J. Campell, “Biochemistry: Second Edition.” 1995, pgs 366-389). Hence, the fatty acid-derived biomaterial described in accordance with the present invention is also bioabsorbable.

#### Methods of Treatment Using the Adhesion Barrier

In general, four types of soft tissue are present in humans: epithelial tissue, *e.g.*, the skin and the lining of the vessels and many organs; connective tissue, *e.g.*, tendons, ligaments, cartilage, fat, blood vessels, and bone; muscle, *e.g.*, skeletal (striated), cardiac, or smooth; and nervous tissue, *e.g.*, brain, spinal cord and nerves. The adhesion barrier in accordance with the present invention can be used to treat injury to these soft tissue areas. Thus, in one embodiment, the adhesion barrier of the present invention can be used for promotion of proliferation of soft tissue for wound healing. Furthermore, following acute trauma, soft tissue can undergo changes and adaptations as a result of healing and the rehabilitative process. Such changes include, but are not limited to, metaplasia, which is conversion of one kind of tissue into a form that is not normal for that tissue; dysplasia, which is the abnormal development of tissue; hyperplasia, which is excessive proliferation of normal cells in the normal tissue arrangement; and atrophy, which is a decrease in the size of tissue due to cell death and resorption or decreased cell proliferation. Accordingly, the fatty acid-derived biomaterial of the present invention can be used for the diminishment or alleviation of at least one symptom associated with or caused by acute trauma in soft tissue.

In accordance with one exemplary embodiment of the present invention, as described below, the adhesion barrier can be used to prevent tissue adhesion. The tissue adhesion can be, for example, a result of blunt dissection. Blunt dissection can be generally described as dissection accomplished by separating tissues along natural cleavage lines without cutting. Blunt dissection is executed using a number of different blunt surgical tools, as is understood by those of ordinary skill in the art. Blunt dissection is often performed in cardiovascular, colo-rectal, urology, gynecology, upper GI, and plastic surgery applications, among others.

After the blunt dissection separates the desired tissues into separate areas, there is often a need to maintain the separation of those tissues. In fact, post surgical adhesions can occur following almost any type of surgery, resulting in serious postoperative complications. The formation of surgical adhesions is a complex inflammatory process in which tissues that normally remain separated in the body come into physical contact with one another and attach to each other as a result of surgical trauma.

It is believed that adhesions are formed when bleeding and leakage of plasma proteins from damaged tissue deposit in the abdominal cavity and form what is called a fibrinous exudate. Fibrin, which restores injured tissues, is sticky, so the fibrinous exudate may attach to adjacent anatomical structures in the abdomen. Post-traumatic or continuous inflammation exaggerates this process, as fibrin deposition is a uniform host response to local inflammation. This attachment seems to be reversible during the first few days after injury because the fibrinous exudates go through enzymatic degradation caused by the release of fibrinolytic factors, most notably tissue-type plasminogen activator (t-PA). There is constant play between t-PA and plasminogen-activator inhibitors. Surgical trauma usually decreases t-PA activity and increases plasminogen-activator inhibitors. When this happens, the fibrin in the fibrinous exudate is replaced by collagen. Blood vessels begin to form, which leads to the development of an adhesion. Once this has occurred, the adhesion is believed to be irreversible. Therefore, the balance between fibrin deposition and degradation during the first few days post-trauma is critical to the development of adhesions (Holmdahl L. *Lancet* 1999; **353**: 1456-57). If normal fibrinolytic activity can be maintained or quickly restored, fibrous deposits are lysed and permanent adhesions can be avoided. Adhesions can appear as thin sheets of tissue or as thick fibrous bands.

Often, the inflammatory response is also triggered by a foreign substance *in vivo*, such as an implanted medical device. The body sees this implant as a foreign substance, and the inflammatory response is a cellular reaction to wall off the foreign material. This inflammation can lead to adhesion formation to the implanted device; therefore a material that causes little to no inflammatory response is desired.

Thus, adhesion barrier of the present invention may be used as a barrier to keep tissues separated to avoid the formation of adhesions, *e.g.*, surgical adhesions. Application examples for adhesion prevention include abdominal surgeries, spinal repair, orthopedic surgeries, tendon and ligament repairs, gynecological and pelvic surgeries, and nerve repair applications. The adhesion barrier may be applied over the trauma site or wrapped around the tissue or organ to limit adhesion formation. The addition of therapeutic agents to the fatty acid-derived biomaterial used in these adhesion prevention applications can be utilized for additional beneficial effects, such as pain relief or

infection minimization. Other surgical applications of adhesion barrier may include using a stand-alone film as a dura patch, buttressing material, internal wound care (such as a graft anastomotic site), and internal drug delivery system. The adhesion barrier may also be used in applications in transdermal, wound healing, and non-surgical fields. The adhesion barrier may be used in external wound care, such as a treatment for burns or skin ulcers. The adhesion barrier may be used without any therapeutic agent as a clean, non-permeable, non-adhesive, non-inflammatory, anti-inflammatory dressing, or the adhesion barrier may be used with one or more therapeutic agents for additional beneficial effects. The adhesion barrier may also be used as a transdermal drug delivery patch when the fatty acid-derived biomaterial is loaded or coated with one or more therapeutic agents.

The process of wound healing involves tissue repair in response to injury and it encompasses many different biologic processes, including epithelial growth and differentiation, fibrous tissue production and function, angiogenesis, and inflammation. Accordingly, the adhesion barrier provides an excellent material suitable for wound healing applications.

Combining fatty acid-based films with tissue fixating materials results in an effective adhesion barrier with fixating and anti-inflammation properties. The resulting adhesion barrier is well-tolerated by the body, reduces adhesions post-surgery, and does not migrate from the target site due to the film's fixating properties. Further, the adhesion barrier is absorbed into the body relatively slowly as compared to conventional CMC-based films, and so facilitates tissue adhesion between the adhesion barrier and the site of treatment for up to 28 days. This provides sufficient residence time to effectively provide post-surgery barrier functionality. Further, combining fatty acid-based films with tissue fixating materials may avoid the need to crosslink the tissue fixating material, reducing the cost and complexity of manufacturing the film.

Numerous modifications and alternative embodiments of the present invention will be apparent to those skilled in the art in view of the foregoing description. Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the best mode for carrying out the present invention.

Details of the structure can vary substantially without departing from the spirit of the invention, and exclusive use of all modifications that come within the scope of the appended claims is reserved. It is intended that the present invention be limited only to the extent required by the appended claims and the applicable rules of law.

All literature and similar material cited in this application, including, patents, patent applications, articles, books, treatises, dissertations and web pages, regardless of the format of such literature and similar materials, are expressly incorporated by reference in their entirety. In the event that one or more of the incorporated literature and similar materials differs from or contradicts this application, including defined terms, term usage, described techniques, or the like, this application controls.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described in any way.

While the present inventions have been described in conjunction with various embodiments and examples, it is not intended that the present teachings be limited to such embodiments or examples. On the contrary, the present inventions encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art.

The claims should not be read as limited to the described order or elements unless stated to that effect. It should be understood that various changes in form and detail can be made without departing from the scope of the appended claims. Therefore, all embodiments that come within the scope and spirit of the following claims and equivalents thereto are claimed.

## CLAIMS

1. An adhesion barrier, comprising:
  - a fatty acid-based material having tissue anti-adhesion characteristics; and
  - a hydrophilic tissue fixating material disposed on or around a surface of the fatty acid-based material;

wherein the fatty acid-based material and the tissue fixating material form the adhesion barrier in such a way that the adhesion barrier is non-inflammatory and fixates to tissue, *in vivo*, for a duration of greater than 10 days.
2. The adhesion barrier of claim 1, wherein the fatty acid-based material is derived from a crosslinked fatty acid-derived biomaterial.
3. The adhesion barrier of claim 1, wherein the fatty acid-based material is created from a fish oil.
4. The adhesion barrier of claim 1, wherein the tissue fixating material comprises carboxymethylcellulose (CMC).
5. The adhesion barrier of claim 1, wherein the tissue fixating material comprises one of a group of sodium carboxymethylcellulose (Na-CMC), poly(ethylene glycol), poly(ethylene oxide), poly(HEMA), poly(N-vinyl pyrrolidone), poly(acrylic acid), carboxymethyl cellulose (CMC), and chitosan.
6. The adhesion barrier of claim 1, wherein the fatty acid-based material is a fatty acid-based film and the tissue fixating material is disposed on only one side of the fatty acid-based film.
7. The adhesion barrier of claim 1, wherein the tissue fixating material is a polyanionic polysaccharide.

8. The adhesion barrier of claim 1, wherein the fatty acid-based material reduces inflammation otherwise associated with the tissue fixating material in absence of the fatty-acid based film.
9. The adhesion barrier of claim 1, further comprising adding a plasticizing agent to the adhesion barrier.
10. The adhesion barrier of claim 9, wherein the plasticizing agent comprises one of a group of glycerin, propylene glycol, poly ethylene glycol, triacetin citrate and triacetin.
11. An adhesion barrier, comprising:
  - a film derived from a fatty acid-derived biomaterial; and
  - a tissue fixating material disposed throughout the film;

wherein the film and the tissue fixating material form the adhesion barrier in such a way that the adhesion barrier is non-inflammatory and fixates to tissue, *in vivo*, for a duration of greater than 10 days.
12. The adhesion barrier of claim 11, wherein the tissue fixating material comprises a tissue fixating coating surrounding the film.
13. The adhesion barrier of claim 11, wherein the tissue fixating material is provided as part of the film.
14. The adhesion barrier of claim 11, wherein the film is an omega-3 fatty acid based film.
15. The adhesion barrier of claim 11, wherein the fatty acid-derived biomaterial is crosslinked.
16. The adhesion barrier of claim 11, wherein the fatty acid-derived biomaterial comprises a fish oil.

17. The adhesion barrier of claim 11, wherein the tissue fixating material comprises a polyanionic polysaccharide.
18. The adhesion barrier of claim 11, wherein the tissue fixating material comprises carboxymethylcellulose (CMC).
19. The adhesion barrier of claim 11, wherein the tissue fixating material comprises sodium carboxymethylcellulose (Na-CMC).
20. The adhesion barrier of claim 11, wherein the fatty acid-derived biomaterial reduces inflammation otherwise associated with the tissue fixating material in absence of the fatty-acid based film.
21. The adhesion barrier of claim 11, wherein the adhesion barrier has a residence time that is sufficient to prevent post-surgical adhesions.
22. The adhesion barrier of claim 11, further comprising a plasticizing agent.
23. The adhesion barrier of claim 22, wherein the plasticizing agent comprises one of a group of glycerin, propylene glycol, poly ethylene glycol, triacetin citrate and triacetin.
24. A method for preparing an adhesion barrier formed of a fatty acid-based film having tissue anti-adhesion characteristics and a hydrophilic tissue fixating material in such a way that the adhesion barrier is non-inflammatory and fixates to tissue, *in vivo*, for a duration of greater than 10 days, the method comprising:
  - providing the fatty acid-based film;
  - providing the tissue fixating material; and
  - combining the fatty acid-based film with the tissue fixating material to form the adhesion barrier.

25. The method of claim 24, wherein the fatty acid-based film is derived from a crosslinked fatty acid-derived biomaterial.
26. The method of claim 24, wherein the fatty acid-based film is created from a fish oil.
27. The method of claim 24, wherein the tissue fixating material comprises carboxymethylcellulose (CMC).
28. The method of claim 24, wherein the tissue fixating material comprises one of a group of sodium carboxymethylcellulose (Na-CMC), poly(ethylene glycol), poly(ethylene oxide), poly(HEMA), poly(N-vinyl pyrrolidone), poly(acrylic acid), carboxymethyl cellulose (CMC), and chitosan.
29. The method of claim 24, wherein the fatty acid-based film does not migrate from a surgical site of placement.
30. The method of claim 24, wherein the tissue fixating material is disposed on only one side of the fatty acid-based film.
31. The method of claim 24, wherein the tissue fixating material coats the fatty-acid based film on more than one side of the fatty acid-based film.
32. The method of claim 24, wherein the tissue fixating material is disposed throughout the fatty-acid based film.
33. The method of claim 24, wherein the tissue fixating material is a polyanionic polysaccharide.

34. The method of claim 24, wherein the fatty acid-based film reduces inflammation otherwise associated with the tissue fixating material in absence of the fatty-acid based film.

35. The method of claim 24, further comprising adding a plasticizing agent to the coating.

36. The method of claim 35, wherein the plasticizing agent comprises one of a group of glycerin, propylene glycol, poly ethylene glycol, triacetin citrate and triacetin.

37. An adhesion barrier, comprising:

fatty-acid based particles derived from a fatty acid-derived biomaterial; and  
an emulsion base comprising a tissue coherent material,

wherein the fatty-acid based particles are mixed with the emulsion base to form the adhesion barrier in such a way that the adhesion barrier is non-inflammatory and *coheres to tissue, in vivo, for a duration of greater than 10 days.*

38. The adhesion barrier of claim 37, wherein the fatty-acid based particles are soaked in a therapeutic agent before being mixed with the emulsion base.


39. The adhesion barrier of claim 37, wherein a mean particle size of the fatty-acid based particles is between about 1 micron and about 50 microns.

40. The adhesion barrier of claim 39, wherein the mean particle size of the fatty-acid based particles is between about 1 micron and about 10 microns.


41. The adhesion barrier of claim 37, wherein the fatty-acid based particles have a distribution of size of about 1-20  $\mu\text{m}$ .

42. The adhesion barrier of claim 37, wherein the fatty-acid based particles have a distribution of size of about , 21-40  $\mu\text{m}$ .


43. The adhesion barrier of claim 37, wherein the fatty-acid based particles have a distribution of size of about 41-150  $\mu\text{m}$ .
44. The adhesion barrier of claim 37, wherein the fatty-acid based particles are omega-3 fatty acid based particles.
45. The adhesion barrier of claim 37, wherein the fatty acid-derived biomaterial is crosslinked.
46. The adhesion barrier of claim 37, wherein the fatty acid-derived biomaterial comprises a fish oil.
47. The adhesion barrier of claim 37, wherein the tissue coherent material comprises a polyanionic polysaccharide.
48. The adhesion barrier of claim 37, wherein the tissue coherent material comprises carboxymethylcellulose (CMC).
49. The adhesion barrier of claim 37, wherein the tissue coherent material comprises sodium carboxymethylcellulose (Na-CMC).




*Figure 1*




*Figure 2*




*Figure 3*



*Figure 4*



*Figure 5*



*Figure 6*

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US 10/52899

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC(8) - A61F 2/00 (2020.01)  
USPC - 424/423

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
USPC: 424/423

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
USPC: 424/78.18, 78.38; 438/622 (see search terms below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
PubWEST (PGPB, USPT, EPAB, JPAB)  
adhesion barriers, tissue fixating, fatty acid, film, films, hydrophilic, fish oil., carboxymethylcellulose, poly(ethylene glycol), poly(ethylene oxide), poly(HEMA), poly(N-vinyl pyrrolidone), poly(acrylic acid), carboxymethyl cellulose (CMC), chitosan,

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2006/0246105 A1 (MOLZ et al.) 2 November 2006 (02.11.2006) para [0013]-[0014], [0021], [0025]-[0026], [0028]-[0031], [0033], [0036]-[0037], [0041], [0056], [0060], [0062], [0067], [0069]-[0070]	1-49
Y	US 5,580,923 A (YEUNG et al.) 3 December 1996 (03.12.1996) abstract; col 1, ln 5-10; col 4, ln 45-58; col 6, ln 21-33; col 12, ln 43-50; col 13, ln 7-13	1-49
Y	US 2009/0208552 A1 (FAUCHER et al.) 20 August 2009 (21.08.2009) Table 1; para [0011]-[0015], [0017]-[0018], [0020], [0045]-[0050], [0055], [0059], [0101], [0109]-[0111], [0113], [0115], [0117], [0119]-[0120], [0131], [0144], [0168], [0171], [0191]	2-10, 14-16, 21, 24-49
Y	US 7,152,611 B2 (BROWN et al.) 26 December 2006 (26.12.2006) table 1, 2; col 13, ln 15-20; col 9, ln 9-11; col 16, ln 15-25	39-43

Further documents are listed in the continuation of Box C.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier application or patent but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search  20 December 2010 (20.12.2010)	Date of mailing of the international search report  10 JAN 2011
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer:  Lee W. Young  PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774